<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04474132</url>
  </required_header>
  <id_info>
    <org_study_id>IRB20-0442</org_study_id>
    <nct_id>NCT04474132</nct_id>
  </id_info>
  <brief_title>Point of Care Testing for Presence of Current and or Previous T. Gondii Infection</brief_title>
  <official_title>Feasibility Study for Finger Prick Testing of Presence of Current and or Previous T. Gondii Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is part of a feasibility study to compare the predicate standard FDA cleared test for
      serum to a point of care test Toxoplasma ICT IgG-IgM BK produced by LD Bio Diagnostic. The
      specificity and sensitivity in testing serum and whole blood will be compared. This study
      includes 70 persons either pregnant or non pregnant.

      This is being done in accordance with FDA requirements for clearance of a testing device . We
      will use a standard FDA cleared test in all studies. The FDA has suggested that we submit a
      pre subQ for a 510K and dual CLIA waiver.

      This allows us also to determine feasibility of use of the predicate test in conjunction with
      the experimental test with volunteers, including men, women, and pregnant women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will determine the feasibility of using the point of care Toxoplasma ICT IgG-IgM
      BK test produced by LD Bio Diagnostic to detect Toxoplasma gondii in clinical settings. The
      result of testing from Toxoplasma ICT IgG-IgM BK test will be compared with the standard
      predicate test. These results will be provided to FDA for consideration for clearance of this
      test.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>subjects are recruited continuously and being tested with the study device as well as with the standard cleared test for the presence of Toxoplasma gondii antibody.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>congruence of Toxoplasma ICT IgG-IgM test and standard predicate test</measure>
    <time_frame>two weeks for initial result and a year for whole study</time_frame>
    <description>Toxoplasma ICT IgG-IgM test is feasible and the test result of the study device is same with the result of standard cleared test</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Toxoplasma Infections</condition>
  <arm_group>
    <arm_group_label>single group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>binary: positive or negative result</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>toxoplasma ICT IgG-IgM BK</intervention_name>
    <description>a point-of-care device, using blood from finger stick to measure the presence or absence of anti Toxoplasma gondii antibody</description>
    <arm_group_label>single group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any adult who is willing to participate in the study

        Exclusion Criteria:

          -  no
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rima McLeod, M.D.</last_name>
    <phone>7738344130</phone>
    <email>rmcleod@uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ying Zhou, Ph.D.</last_name>
    <phone>7738344120</phone>
    <email>yzhou@bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rima McLeod, M.D.</last_name>
      <phone>773-834-4130</phone>
      <email>rmcleod@uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ying Zhou, Ph.D.</last_name>
      <phone>7738344120</phone>
      <email>yzhou@bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lykins J, Li X, Levigne P, Zhou Y, El Bissati K, Clouser F, Wallon M, Morel F, Leahy K, El Mansouri B, Siddiqui M, Leong N, Michalowski M, Irwin E, Goodall P, Ismail M, Christmas M, Adlaoui EB, Rhajaoui M, Barkat A, Cong H, Begeman IJ, Lai BS, Contopoulos-Ioannidis DG, Montoya JG, Maldonado Y, Ramirez R, Press C, Peyron F, McLeod R. Rapid, inexpensive, fingerstick, whole-blood, sensitive, specific, point-of-care test for anti-Toxoplasma antibodies. PLoS Negl Trop Dis. 2018 Aug 16;12(8):e0006536. doi: 10.1371/journal.pntd.0006536. eCollection 2018 Aug.</citation>
    <PMID>30114251</PMID>
  </results_reference>
  <results_reference>
    <citation>Begeman IJ, Lykins J, Zhou Y, Lai BS, Levigne P, El Bissati K, Boyer K, Withers S, Clouser F, Noble AG, Rabiah P, Swisher CN, Heydemann PT, Contopoulos-Ioannidis DG, Montoya JG, Maldonado Y, Ramirez R, Press C, Stillwaggon E, Peyron F, McLeod R. Point-of-care testing for Toxoplasma gondii IgG/IgM using Toxoplasma ICT IgG-IgM test with sera from the United States and implications for developing countries. PLoS Negl Trop Dis. 2017 Jun 26;11(6):e0005670. doi: 10.1371/journal.pntd.0005670. eCollection 2017 Jun.</citation>
    <PMID>28650970</PMID>
  </results_reference>
  <results_reference>
    <citation>Gomez CA, Budvytyte LN, Press C, Zhou L, McLeod R, Maldonado Y, Montoya JG, Contopoulos-Ioannidis DG. Evaluation of Three Point-of-Care Tests for Detection of Toxoplasma Immunoglobulin IgG and IgM in the United States: Proof of Concept and Challenges. Open Forum Infect Dis. 2018 Oct 29;5(10):ofy215. doi: 10.1093/ofid/ofy215. eCollection 2018 Oct.</citation>
    <PMID>30393749</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>toxoplasma</keyword>
  <keyword>test</keyword>
  <keyword>feasibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

